Product Information
LORAZEPAM 2 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0731 per EA under NDC 64980062950. Its NADAC has been published 32 times since Feb 25, 2026.
FDA first approved this application on Jul 24, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980062950
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LORAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA218597FDA Approved
7/24/2025
TE Code
AB
On Market Since
7/24/2025
Pharmacological Classes
Price Statistics
The NADAC for LORAZEPAM 2 MG TABLET has been published 32 times since Feb 25, 2026, and over the history we have for it it has risen 5.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0731 per EA |
|---|---|
| All-time high | $0.0731 (Sep 30, 2026) |
| All-time low | $0.0695 (Feb 25, 2026) |
| 52-week high | $0.0731 |
| 52-week low | $0.0695 |
| Median price | $0.0700 |
| Average price | $0.0703 |
| Largest weekly change | +4.9% (Sep 23, 2026) |
| Weeks tracked | 32 |
| Tracking since | Feb 25, 2026 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 42% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lorazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LORAZEPAM 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LORAZEPAM 2 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0731 per EA (NDC 64980062950), effective Sep 30, 2026.
How has the price of LORAZEPAM 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for LORAZEPAM 2 MG TABLET has risen 5.2%. It has been tracked across 32 weekly CMS publications since Feb 25, 2026.
What are the highest and lowest recorded NADAC prices for LORAZEPAM 2 MG TABLET?
Since Feb 25, 2026, the NADAC for LORAZEPAM 2 MG TABLET has ranged from a low of $0.0695 (Feb 25, 2026) to a high of $0.0731 (Sep 30, 2026), with a median of $0.0700 per EA.
Are there cheaper alternatives to LORAZEPAM 2 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LORAZEPAM 2 MG TABLET, is $0.0424 per EA — about 42% below LORAZEPAM 2 MG TABLET.
Who manufactures LORAZEPAM 2 MG TABLET?
LORAZEPAM 2 MG TABLET (NDC 64980062950) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.